Pasotuxizumab

N/A

Report date: 2026/03/19 16:47:07

Base Information

Drug NamePasotuxizumab
Drug Alias NameMT-112BAY-2010112AMG-212
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized +[5] 
Mechanisms of ActionCD3 T-cell engagersProstate-Specific Membrane Antigen inhibitors
TargetsProstate-Specific Membrane AntigenT cell surface glycoprotein CD3
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustriaGermany
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeOne Medicines LtdBayer AG
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A